I Want To...
I Want To...
Find Research Faculty
Enter the last name, specialty or keyword for your search below.
School of Medicine
I Want to...
Christine Anne Pratilas, M.D.
Associate Professor of Oncology
Specializes in: Adolescents (12-18 years), Children (1-11 years), Infants (up to 1 year)
Expertise: Bone Cancer, Clinical Trials, Ewing's Sarcoma, Medical Oncology, Melanoma, Osteosarcoma, Pediatric Cancer, Rhabdomyosarcoma, Sarcoma and Musculoskeletal Tumors , Soft Tissue Sarcoma ...read more
Research Interests: oncogenes; BRAF; NF1; RAS; cancer cell signaling pathways; molecularly targeted therapy; RAF and MEK inhibitor therapy; pediatric sarcomas; pediatric phase I clinical trials ...read more
Request an Appointment
I live in Maryland
Request an appointment through My
I live outside of Maryland
I live outside of the United States
The Johns Hopkins Hospital (Main Entrance)
Appointment Phone: 410-955-8751
1800 Orleans St.
The Charlotte R. Bloomberg Children's Center Building, 11th Floor
Baltimore, MD 21287 map
Dr. Christine Pratilas is a pediatric medical oncologist at the Sidney Kimmel Comprehensive Cancer Center and Associate Professor of Oncology, Pediatrics & Cellular and Molecular Medicine at the Johns Hopkins University School of Medicine. She joined the Hopkins pediatric sarcoma team in 2014.
Dr. Pratilas received her undergraduate degree in Biology from Drew University in New Jersey and her medical degree from the Robert Wood Johnson Medical School (now Rutgers University), where she also completed her internship and residency from 1999 to 2002. From 2002 to 2005 she was a fellow in hematology and oncology in the Memorial Sloan Kettering Cancer Center (MSKCC) Department of Pediatrics, and in the Department of Pediatric Hematology and Oncology at New York Weill Cornell Medical Center. She worked for three years as a postdoctoral research fellow in Dr. Neal Rosen’s Molecular Oncogenesis Laboratory at MSKCC.
From 2006 to 2014 she was attending in Pediatric Oncology at MSKCC, initially as a member of the Developmental Therapeutics & Lymphoma team. In 2011 she began her specialization in the care of pediatric sarcoma patients.
During her years in the lab of Dr. Rosen, a distinguished molecular pharmacologist and cell biologist, Dr. Pratilas focused her research on signal transduction, which involves figuring out how a cell’s internal molecular pathways work, and how those pathways can be molecularly controlled. This knowledge is the basis for developing promising new molecularly targeted cancer therapies, which is the focus of Dr. Pratilas’s research. One of her most important contributions to date has been to advance our understanding of how certain proteins that can be mutated in cancer, known as RAF kinases, affect a cancer cell’s behavior.
Dr. Pratilas continues her research on signal transduction pathways, concentrating on pediatric sarcomas, in order to develop novel therapeutics for children with these tumors.
- Associate Professor of Oncology
- Associate Professor of Pediatrics
Centers & Institutes
- MD; Pediatrics, Rutgers - Robert Wood Johnson Medical School (1999)
- Rutgers - Robert Wood Johnson University Hospital / Pediatrics (2002)
- Memorial Sloan-Kettering Cancer Center / Hematology and Oncology (2005)
- American Board of Pediatrics / Pediatric Hematology (2006)
- American Board of Pediatrics / Pediatrics (2002)
Research & Publications
Clinical Trial KeywordsMolecularly targeted therapy, pediatric cancer, solid tumor
- Study of RXDX-101 in Children With Recurrent or Refractory Solid Tumors and Primary CNS Tumors, With or Without TRK, ROS1, or ALK Fusions
- Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Subjects With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS)
- Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
- Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma
- A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma
10/12/10 Awarded, Biomarkers for Cancer Treatment - U.S. Patent No. 7,812,143 B2; Inventors: Pratilas, C; Rosen, N
Patent # U.S. Patent No. 7,812,143 B2 | 10/12/2010
Academic Affiliations & Courses
Graduate Program Affiliation
Cellular and Molecular Medicine
Activities & Honors
- Young Investigator Award, Melanoma Research Alliance, 2011
- ASCO Foundation Young Investigators Award, 2004
- AACR Scholar-in-Training Award, 2004
- Doris Duke Award, MSKCC, 2004
- Medical Society Scholarship, Morris County, NJ, 1997
- Magna cum laude, Phi Beta Kappa, Drew University, 1995
- Merit Scholarship, Drew University, 1992 - 1995
- Edward Bloustein Garden State Scholarship, New Jersey, 1992 - 1995
- American Association for Cancer Research, 2003
- American Society of Clinical Oncology, 2003
- Children’s Oncology Group, 2008
- AACR Pediatric Cancer Working Group, 2012